000304281 001__ 304281
000304281 005__ 20250907022516.0
000304281 0247_ $$2doi$$a10.1111/bpa.70035
000304281 0247_ $$2pmid$$apmid:40887057
000304281 0247_ $$2ISSN$$a1015-6305
000304281 0247_ $$2ISSN$$a1750-3639
000304281 0247_ $$2altmetric$$aaltmetric:180891034
000304281 037__ $$aDKFZ-2025-01821
000304281 041__ $$aEnglish
000304281 082__ $$a610
000304281 1001_ $$00000-0001-5453-5201$$aWesseling, Pieter$$b0
000304281 245__ $$acIMPACT-NOW update 11: Proposal on adaptation of diagnostic criteria for IDH- and H3-wildtype diffuse high-grade gliomas and for posterior fossa ependymal tumors.
000304281 260__ $$aOxford$$bWiley-Blackwell$$c2025
000304281 3367_ $$2DRIVER$$aarticle
000304281 3367_ $$2DataCite$$aOutput Types/Journal article
000304281 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1756813052_26697
000304281 3367_ $$2BibTeX$$aARTICLE
000304281 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000304281 3367_ $$00$$2EndNote$$aJournal Article
000304281 500__ $$aepub
000304281 520__ $$aThe Consortium to Inform Molecular and Practical Approaches to Central Nervous System Tumor Taxonomy (cIMPACT-NOW) updates provide guidelines for the diagnosis of central nervous system (CNS) tumors and suggestions for future World Health Organization (WHO) classification. Following publication of the fifth edition WHO Classification of CNS Tumors (WHO CNS5) in 2021, the cIMPACT-NOW working group 'Clarification' reviewed WHO CNS5 and prioritized two topics for further elucidation: (a) distinction of Glioblastoma, IDH-wildtype from Diffuse pediatric-type high-grade glioma, H3-wildtype, and IDH-wildtype and (b) clarification of subgroups of posterior fossa (PF) ependymal tumors. Recommendations regarding the IDH- and H3-wildtype diffuse high-grade gliomas include: (1) use caution assigning CNS WHO grade 4 (diagnosis of Glioblastoma, IDH-wildtype) to a 'TERT promoter only', histologically low-grade, IDH-wildtype tumor; (2) EGFR gene amplification and +7/-10 chromosome copy number alterations should not be used as solitary defining features for diagnosing high-grade gliomas as Glioblastoma, IDH-wildtype in patients <40 years of age; (3) Diffuse pediatric-type high-grade glioma, H3-wildtype, and IDH-wildtype should be considered in the differential diagnosis in adults, especially those <40 years of age; (4) PDGFRA alteration, EGFR alteration, or MYCN amplification count as key molecular features of Diffuse pediatric-type high-grade glioma, H3-wildtype, and IDH-wildtype only in patients <25 years. Guidelines for improved diagnosis of posterior fossa ependymal tumors include: (1) immunohistochemical demonstration of nuclear EZHIP supports classification as PF group A ependymoma; (2) a PF ependymoma with retained nuclear H3 K27me3 expression and no nuclear EZHIP overexpression for which DNA methylation profiling is not performed should be considered as PF ependymoma, 'not otherwise specified'; (3) for emerging tumors not included in WHO CNS5, 'not elsewhere classified' (NEC) can be added to the diagnosis. Of note, these recommendations are not formal changes to the WHO definitions and diagnostic criteria but are intended to provide diagnostic guidance in advance of WHO CNS6.
000304281 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000304281 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000304281 650_7 $$2Other$$aGlioblastoma, IDH‐wildtype
000304281 650_7 $$2Other$$aWHO classification
000304281 650_7 $$2Other$$acIMPACT‐NOW
000304281 650_7 $$2Other$$aclarification
000304281 650_7 $$2Other$$adiffuse pediatric‐type high‐grade glioma
000304281 650_7 $$2Other$$aposterior fossa ependymoma
000304281 7001_ $$0P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c$$aCapper, David$$b1$$udkfz
000304281 7001_ $$00000-0002-1419-9837$$aReifenberger, Guido$$b2
000304281 7001_ $$00000-0002-4315-9316$$aSarkar, Chitra$$b3
000304281 7001_ $$00000-0003-2618-4402$$aHawkins, Cynthia$$b4
000304281 7001_ $$00000-0002-8300-7261$$aPerry, Arie$$b5
000304281 7001_ $$aKleinschmidt-DeMasters, Bette$$b6
000304281 7001_ $$00000-0002-6812-2149$$aKomori, Takashi$$b7
000304281 7001_ $$aPaulus, Werner$$b8
000304281 7001_ $$00000-0001-8724-2034$$aSantosh, Vani$$b9
000304281 7001_ $$00000-0001-5710-5127$$avan den Bent, Martin$$b10
000304281 7001_ $$00000-0002-1748-174X$$aWeller, Michael$$b11
000304281 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan$$b12$$udkfz
000304281 7001_ $$00000-0002-5019-2683$$aTabori, Uri$$b13
000304281 7001_ $$00000-0002-3604-887X$$aFigarella-Branger, Dominique$$b14
000304281 7001_ $$00000-0003-0997-4728$$aOrr, Brent A$$b15
000304281 7001_ $$00000-0002-9423-4099$$aLouis, David N$$b16
000304281 773__ $$0PERI:(DE-600)2029927-8$$a10.1111/bpa.70035$$gp. e70035$$pnn$$tBrain pathology$$vnn$$x1015-6305$$y2025
000304281 909CO $$ooai:inrepo02.dkfz.de:304281$$pVDB
000304281 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000304281 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000304281 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000304281 9141_ $$y2025
000304281 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2024-12-11$$wger
000304281 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-11
000304281 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-11
000304281 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-08-08T17:07:24Z
000304281 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-08-08T17:07:24Z
000304281 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2024-08-08T17:07:24Z
000304281 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-11
000304281 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-11
000304281 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-11
000304281 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-11
000304281 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-11
000304281 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-11
000304281 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-11
000304281 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBRAIN PATHOL : 2022$$d2024-12-11
000304281 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-11
000304281 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-11
000304281 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bBRAIN PATHOL : 2022$$d2024-12-11
000304281 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-11
000304281 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-11
000304281 9201_ $$0I:(DE-He78)BE01-20160331$$kBE01$$lDKTK Koordinierungsstelle Berlin$$x0
000304281 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x1
000304281 980__ $$ajournal
000304281 980__ $$aVDB
000304281 980__ $$aI:(DE-He78)BE01-20160331
000304281 980__ $$aI:(DE-He78)B062-20160331
000304281 980__ $$aUNRESTRICTED